- About WXPress
- WXPress is your window into the world of WuXi AppTec and our global partners.
- Sitemap
- Events
- Contact
- Please reach out with any business inquires.
- communications@wuxiapptec.com
© 2026 WuXi AppTec. All Rights Reserved.Privacy Policy
September 9, 2021 ~ September 9, 2021
8am - 10:30am PDT | 7pm - 9:30 pm PDT
11am - 1:30pm EDT | 10pm - 12:30am EDT
Dear colleagues and friends,
Thank you for participating in our global webinar, “Duchenne Muscular Dystrophy: Charting the Path for New Therapeutics and Better Care,” which was co-organized with Parent Project Muscular Dystrophy (PPMD) and CureDuchenne. We are delighted that more than 1500 registered from 36 countries worldwide, coming together to raise awareness of this devastating rare disease, and to foster collaborations towards better medicines for patients.
For those who registered but couldn’t make it, or who couldn’t stay through the entire webinar, we have prepared a replay link. Please click HERE to watch the on-demand video.
At WuXi AppTec, we firmly believe in a future where “every drug can be made and every disease can be treated”. That future is only possible if we all work together.
Thank you again, and we hope to see you at our next episode of WuXi AppTec Rare Disease webinar series.
Hui Cai, VP and Head of Content, WuXi AppTec
Pat Furlong, Founding President & CEO, Parent Project Muscular Dystrophy
Debra Miller, CEO & Founder, CureDuchenne
Filippo Buccella, Founder, Parent Project Italy APS
Huigu Chen, President, Shanghai Jiai Myopathy Care Center, China
Tali Kaplan, Co-Founder & CEO, Little Steps Association for Patients with Duchenne & Becker Muscular Dystrophy, Israel
Sherena Loh, Director, Muscular Dystrophy Association (Singapore)
Kevin Flanigan, Director, Center for Gene Therapy, Professor, Pediatrics & Neurology, Nationwide Children’s Hospital
Stanley Nelson, Professor of Human Genetics, Center for Duchenne Muscular Dystrophy, David Geffen School of Medicine at UCLA
Richard Parad, Associate Professor of Pediatrics, Harvard Medical School, Department of Pediatric Newborn Medicine, Brigham and Women’s Hospital
Moderator: Hawken Miller, Features Writer, BioNews
A Conversation between Pat Furlong, Founding President & CEO, Parent Project Muscular Dystrophy and Debra Miller, CEO & Founder, CureDuchenne
Michael Binks, VP & Head of Clinical Research in the Rare Disease Research Unit at Pfizer
Paula Clemens, Professor & Vice Chair, Neurology, University of Pittsburgh School of Medicine
Nathalie Goemans, Professor, Neuromuscular Reference Centre for Children, Department of Pediatric Neurology, University Hospitals Leuven, Belgium
Moderator: Timothy Franson, Principal, Faegre Drinker Consulting and formerly VP Global Regulatory Affairs, Eli Lilly & Co and Chief Medical Officer of YourEncore
Rhonda Bassel-Duby, Professor, Department of Molecular Biology, University of Texas Southwestern Medical Center
Ashish Dugar, SVP & Global Head of Medical Affairs, Dyne Therapeutics
Jane Larkindale, VP, Clinical Sciences, PepGen
Art Levin, CSO, Avidity Biosciences
Stuart Peltz, Founder & CEO, PTC Therapeutics
Moderator: Richard Soll, Head of Boston Office and Senior Advisor of Strategic Initiatives, WuXi AppTec
Michael Binks, VP & Head of Clinical Research in the Rare Disease Research Unit at Pfizer
Yi Dai, Associate Professor, Department of Neurology, Peking Union Medical College Hospital, China
Xihua Li, Director, Department of Neuromuscular Disease, Children’s Hospital of Fudan University, China
Stanley Nelson, Professor of Human Genetics, Center for Duchenne Muscular Dystrophy, David Geffen School of Medicine at UCLA
Richard Parad, Associate Professor of Pediatrics, Harvard Medical School, Department of Pediatric Newborn Medicine, Brigham and Women’s Hospital
Stacey Tay, Senior Consultant, Department of Paediatrics, Khoo Teck Puat - National University Children's Medical Institute, National University Hospital, Singapore
Hui Cai, VP and Head of Content, WuXi AppTec
